Vivid Seats: Q2 Earnings Today, But The Real Question Is Whether Revenue Has Bottomed

Vivid Seats (NASDAQ: SEAT) reports second quarter 2026 results today, August 4. The stock sits at $7.96, up about 3.4% on the session, after a brutal 52% annual return that has dragged it from a 52-week high of $18.73 to the low $7s. It is trading at a market cap of $87 million with an enterprise value of $331 million - a 0.62x EV/sales multiple that prices the business for near-zero. At those levels, the rating question is not whether the company is flawed. It is whether the decline has stabilized enough that this multiple actually represents a floor.

The revenue trend is the only thing that matters

Vivid Seats revenue has fallen for five consecutive quarters, dropping from $198.3 million in Q2 2024 to $125.8 million in Q1 2026. That is a 36% decline in eighteen months. Analysts expect approximately $122.1 million for Q2 2026, which would be another small step down from Q1's $125.8 million.

But the trajectory matters more than the absolute level. Revenue decline has decelerated sharply. Q2 2025 saw a 28% year-over-year drop. Q3 2025 was down 27%. Q4 2025 was down 36%, but that quarter included a $31.83 EPS bomb that distorted the headline numbers. Q1 2026 revenue of $125.8 million was essentially flat quarter-over-quarter versus Q4 2025's $126.8 million, and the year-over-year decline was to -29% - the same pace as the prior year. The quarterly revenue decline rate has gone from -10% to -5% to near-zero.

If Q2 2026 revenue holds at $120 million-plus, the argument is that the revenue decline has bottomed. If it falls below $115 million, the decline is still in gear and the current multiple is justified.

The cost-cutting program is real, but the balance sheet is the trap

Management announced a $25 million annualized cost reduction program in August 2025, which they expected to fully implement by year-end. That program was designed to right-size the organization for the current revenue environment. For a company whose revenue has fallen from nearly $200 million to about $125 million, that is not cosmetic trimming - it is a structural necessity.

Gross margins remain attractive at 68.4%, which shows the marketplace model still generates healthy spreads on ticket transactions. The problem is that operating costs have not fallen fast enough. Operating margins sit at -147%, EBITDA margins at -138%, and free cash flow was negative $18.8 million over the trailing twelve months. Return on invested capital is -132%.

Management guided in May for full-year 2026 revenue of approximately $575 million, adjusted EBITDA of approximately $45 million, and unlevered free cash flow of approximately $35 million. If they hit that, it means the business can produce positive free cash flow despite the revenue decline - which would be the inflection point investors need to see.

But here is where the balance sheet becomes the dominant risk. Total debt stands at $787 million. Cash is $144 million. Net debt is approximately $243 million according to reported figures, though the raw math between gross debt and cash suggests the debt burden is heavier - the company likely carries preferred equity or other instruments that affect the net calculation. Total equity is negative $95 million. The current ratio is 66%, below the 100% threshold that signals a company can cover its short-term obligations from current assets.

That balance sheet is the reason this stock trades at 0.62x EV/sales. A company with nearly $800 million in debt and negative equity is one material misstep from needing to raise capital, dilute shareholders, or restructure. The cost-cutting program addresses the income statement, but it does not solve the debt overhang.

Valuation: cheap by every metric, but cheap for structural reasons

Metric	Vivid Seats (SEAT)
EV/Sales (TTM)	0.62x
P/Sales (TTM)	0.16x
Market Cap	$87.5M
Enterprise Value	$330.5M
Gross Margin	68.4%
Operating Margin	-147%
FCF (TTM)	-$18.8M
Total Debt	$787M
Cash	$143.6M
Net Equity	-$95.4M

At 0.16x trailing sales, Vivid Seats is priced as if it will go to zero. The GuruFocus intrinsic value model places the stock at $4.01, implying 48% downside from the $7.74 July 31 close. The average Wall Street analyst target across eight analysts is $10.37, implying 34% upside. The GuruFocus value model is notoriously harsh on loss-making names with negative equity, so I weight it less than the cash flow path. The analyst targets, by contrast, assume the 2026 guidance gets hit - $45 million of adjusted EBITDA and $35 million of unlevered free cash flow - which would transform the valuation story.

The gap between the $4.01 intrinsic value and the $10.37 average analyst target is the gap between "this company can't service its debt" and "this company hits its turnaround guidance." Investors need to pick which camp they are in.

What to watch in today's Q2 report

Three metrics will determine whether the stock can hold above the $7 level:

• Revenue versus the $122.1 million estimate. A beat or even an in-line result would confirm the revenue decline has flattened. A miss below $118 million would signal the bottom is still ahead.

• Any update to 2026 guidance. Management guided for $575 million in full-year revenue in May. Q1 delivered $125.8 million, which puts the full-year run rate on track. If management reaffirms or raises guidance, the market will reward it. If they cut it, the stock will retest the $5 low.

• Cash burn and debt commentary. The $787 million debt load is the elephant in the room. Any discussion of refinancing, maturity extensions, or additional cost savings beyond the $25 million program would be material. Conversely, any language about liquidity pressure would be deeply negative.

Rating: Hold - too much balance sheet risk for a Buy, too cheap to ignore

Vivid Seats is in the "too cheap to ignore but not out of the woods" category. The revenue decline appears to be flattening, the cost-cutting program is underway, and the gross margin remains structurally sound at 68%. At 0.16x sales, the downside from valuation alone is limited - the stock would need to nearly halve again to price in total failure.

But the $787 million debt load, negative equity, and negative free cash flow create real solvency risk. A Buy rating requires proof that the business can service that debt, and that proof does not exist until free cash flow turns positive and stays there. The 2026 guidance of $35 million unlevered free cash flow would be that proof, but guidance is not proof.

I am rating this a Hold. The valuation reset has already done most of the work. If Q2 revenue holds near or above the $122 million estimate and 2026 guidance stands, the case for upgrading to a Buy strengthens materially. If revenue falls further or guidance gets cut, the $5 low is still in play. The catalyst clock is set for today's earnings - the next decision point arrives then.